Ostroff: Administration Coming Up To Speed On Planned FDA Guidances
Executive Summary
There has been a dearth of guidances from US FDA since Donald Trump's inauguration, but the acting FDA commissioner says that simply reflects the new administration catching up on what's in the pipeline. In a speech at FDLI's annual meeting, Stephen Ostroff struck a positive tone.
You may also be interested in...
Gottlieb Becomes FDA Commissioner With Immediate Issues Pending
Confirmation comes with fewest votes of any recent commissioner as FDA dealing with budget, user fees and other issues.
Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support
At FDLI, both US FDA acting Commissioner Stephen Ostroff and BIO’s Kay Holcombe strike note of anticipating positive outcomes for FDA, despite current political and regulatory uncertainties. FDA has been through challenges before, and “we have come through them even stronger," Ostroff assures meeting.
Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market
The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.